ImmunityBio (IBRX) Jumps Ahead of Oncology Event

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) experienced a significant share price increase of 14.55%, closing at $6.93, as investors prepared for its upcoming participation in the American Society of Clinical Oncology (ASCO) event [1][6]. Company Developments - ImmunityBio is set to participate in the 2026 ASCO Genitourinary Cancers Symposium from February 26 to 28 in San Francisco, focusing on research and treatments for genitourinary cancers [2]. - Earlier this year, ImmunityBio reported a remarkable 700% increase in sales from its cancer therapy Anktiva and announced plans to expand operations into Saudi Arabia, where it will sell Anktiva for lung cancer patients following FDA approval [3]. Market Context - Lung cancer is a prevalent cancer type in Saudi Arabia, indicating a significant market opportunity for ImmunityBio's products [3].